Advertisement

Advertisement

TOVX Stock Latest News

Theriva Biologics announces results from VIRAGE Phase 2b trial of VCN-01

The FlyTheriva Biologics announces results from VIRAGE Phase 2b trial of VCN-01

HC Wainwright Starts Theriva (TOVX) at Buy on Undervalued Oncolytic Virus Platform and Advancing VCN-01 Pancreatic Cancer Program

PremiumRatings

HC Wainwright Starts Theriva (TOVX) at Buy on Undervalued Oncolytic Virus Platform and Advancing VCN-01 Pancreatic Cancer Program

2M ago

Theriva Begins VIRAGE2 Trial in Metastatic Pancreatic Cancer

PremiumCompany Announcements

Theriva Begins VIRAGE2 Trial in Metastatic Pancreatic Cancer

2M ago

Theriva Biologics Expands Stock Incentive and Governance Plans

PremiumCompany Announcements

Theriva Biologics Expands Stock Incentive and Governance Plans

3M ago

Theriva Biologics launches VIRAGE2 metastatic pancreatic trial

PremiumCompany Announcements

Theriva Biologics launches VIRAGE2 metastatic pancreatic trial

3M ago

Theriva Biologics gets regulatory authorization to proceed with VIRAGE2 in Spain

PremiumThe FlyTheriva Biologics gets regulatory authorization to proceed with VIRAGE2 in Spain

3M ago

Theriva Biologics highlights promising VCN-01 Phase 1 results

Company Announcements

Theriva Biologics highlights promising VCN-01 Phase 1 results

4M ago

Theriva Biologics Faces Quorum Issue Delaying Warrant Vote

Company Announcements

Theriva Biologics Faces Quorum Issue Delaying Warrant Vote

5M ago

3 Penny Stocks to Watch Now, 4/21/26

PremiumMarket News

3 Penny Stocks to Watch Now, 4/21/26

6M ago

Theriva Biologics Highlights Positive VCN-01 Pancreatic Cancer Data

PremiumCompany Announcements

Theriva Biologics Highlights Positive VCN-01 Pancreatic Cancer Data

6M ago

Theriva Biologics to present additional data on Phase 2b VCN-01Clinical Trial

PremiumThe Fly

Theriva Biologics to present additional data on Phase 2b VCN-01Clinical Trial

6M ago

Theriva Biologics Faces Delays in Warrant Approval Meeting

PremiumCompany Announcements

Theriva Biologics Faces Delays in Warrant Approval Meeting

6M ago

Theriva Biologics upgraded to Buy at Maxim on clearer VCN-01 path

PremiumThe FlyTheriva Biologics upgraded to Buy at Maxim on clearer VCN-01 path

7M ago

Theriva Biologics upgraded to Buy from Hold at Maxim

The Fly

Theriva Biologics upgraded to Buy from Hold at Maxim

7M ago

Theriva Biologics Advances VCN-01 Into Pivotal Phase 3

Company Announcements

Theriva Biologics Advances VCN-01 Into Pivotal Phase 3

7M ago

Theriva Biologics announces outcome of Type B End-of-Phase 2 meeting with FDA

PremiumThe Fly

Theriva Biologics announces outcome of Type B End-of-Phase 2 meeting with FDA

7M ago

Theriva Biologics price target lowered to $4 from $7 at Alliance Global

PremiumThe Fly

Theriva Biologics price target lowered to $4 from $7 at Alliance Global

7M ago

Theriva Biologics reports FY25 EPS ($2.08) vs. ($19.03) last year

PremiumThe Fly

Theriva Biologics reports FY25 EPS ($2.08) vs. ($19.03) last year

7M ago

Theriva Biologics sees cash runway into 1Q27

PremiumThe Fly

Theriva Biologics sees cash runway into 1Q27

7M ago

Theriva Licenses SYN-020, Refocuses on Cancer Pipeline

PremiumCompany AnnouncementsTheriva Licenses SYN-020, Refocuses on Cancer Pipeline

8M ago

Theriva Biologics licenses SYN-020 to Rasayana Therapeutics

The Fly

Theriva Biologics licenses SYN-020 to Rasayana Therapeutics

8M ago

Theriva Biologics Faces Delay in Warrant Approval Meeting

Company Announcements

Theriva Biologics Faces Delay in Warrant Approval Meeting

8M ago

Trending

S&P 500

―

Dow Jones

―

Nasdaq 100

―

More Trending Stocks >